Patents by Inventor Wolfgang Fraunhofer
Wolfgang Fraunhofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190358322Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: ApplicationFiled: December 20, 2018Publication date: November 28, 2019Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Publication number: 20190231978Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.Type: ApplicationFiled: January 18, 2019Publication date: August 1, 2019Inventors: Wolfgang Fraunhofer, James Cameron, Linas P. Laurusonis
-
Publication number: 20190211093Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.Type: ApplicationFiled: August 10, 2018Publication date: July 11, 2019Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
-
Patent number: 10183117Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.Type: GrantFiled: October 16, 2015Date of Patent: January 22, 2019Assignee: AbbVie Inc.Inventors: Wolfgang Fraunhofer, James Cameron, Linas P. Laurusonis
-
Publication number: 20170143828Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: ApplicationFiled: February 2, 2017Publication date: May 25, 2017Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Publication number: 20160222101Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: ApplicationFiled: April 11, 2016Publication date: August 4, 2016Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Publication number: 20160106921Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.Type: ApplicationFiled: October 16, 2015Publication date: April 21, 2016Inventors: Wolfgang Fraunhofer, James Cameron, Linas P. Laurusonis
-
Publication number: 20160017030Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.Type: ApplicationFiled: July 30, 2015Publication date: January 21, 2016Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
-
Publication number: 20150361170Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: ApplicationFiled: July 10, 2015Publication date: December 17, 2015Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Patent number: 9085619Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: GrantFiled: October 3, 2014Date of Patent: July 21, 2015Assignee: AbbVie Biotechnology LTD.Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe
-
Publication number: 20150183863Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.Type: ApplicationFiled: June 19, 2014Publication date: July 2, 2015Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Publication number: 20150166648Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.Type: ApplicationFiled: June 5, 2014Publication date: June 18, 2015Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
-
Publication number: 20150071944Abstract: The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation.Type: ApplicationFiled: November 6, 2014Publication date: March 12, 2015Inventors: Ivan R.S. Correia, Czeslaw H. Radziejewski, Wolfgang Fraunhofer, Nicholas William Warne, Angela Kantor
-
Patent number: 8940873Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.Type: GrantFiled: February 7, 2013Date of Patent: January 27, 2015Assignee: AbbVie Inc.Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
-
Publication number: 20150023977Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: ApplicationFiled: October 3, 2014Publication date: January 22, 2015Applicant: ABBVIE INC.Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Publication number: 20140377275Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.Type: ApplicationFiled: August 29, 2014Publication date: December 25, 2014Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
-
Patent number: 8883146Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: GrantFiled: February 22, 2013Date of Patent: November 11, 2014Assignee: AbbVie Inc.Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Patent number: 8821865Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.Type: GrantFiled: November 11, 2011Date of Patent: September 2, 2014Assignee: Abbvie Biotechnology Ltd.Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick
-
Patent number: 8772458Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.Type: GrantFiled: February 22, 2013Date of Patent: July 8, 2014Assignee: AbbVie Biotechnology LtdInventors: Anette Koenigsdorfer, Stefan Gottschalk, Hans-Juergen Krause, Gerhard Winter, David W. Borhani, Wolfgang Fraunhofer
-
Patent number: 8753839Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.Type: GrantFiled: August 8, 2008Date of Patent: June 17, 2014Assignee: Abbvie Inc.Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk